Chapter from the book *What Should We Know About Prevented, Diagnostic, and Interventional Therapy in Coronary Artery Disease*


Interested in publishing with InTechOpen?
Contact us at [book.department@intechopen.com](mailto:book.department@intechopen.com)
1. Introduction

Ultrasound techniques represent easy and useful diagnostic tools able to detect cardiac morphological and functional damage.

Transthoracic echocardiography is a reliable, cheap and non-invasive technique that allows an accurate evaluation of valvular abnormalities, pericardial diseases and ventricular wall motion defects, while Doppler analysis is useful to study left ventricular diastolic filling, valvular function and pulmonary pressures. Rexhepaj et al [1] found significant differences in early diastolic flow velocity (E), atrial flow velocity (A) and E/A ratio in rheumatoid arthritis (RA) patients compared to the control group, suggesting that a subclinical impairment of left and right ventricular function is present in RA patients, when left ventricular thickness, dimensions and myocardial performance indexes were still normal.

A new clinical application of ultrasound imaging is represented by the transthoracic dipyridamole stress echocardiography with coronary flow reserve (CFR) evaluation. CFR is assessed in the distal left anterior descending coronary artery (LAD) defined by the ratio between peak diastolic velocity during stress and at baseline (Fig. 1-2). It is a highly sensitive (>90%) diagnostic marker for coronary artery disease (CAD) [2, 3] and, when associated with the evaluation of the regional wall motion analysis, it becomes also highly specific [4]. In literature reports, a value of CFR < 2 has been shown to accurately predict the presence of coronary stenosis. In absence of epicardial coronary stenosis, an abnormal CFR may reflect an...
impaired coronary microcirculation in patients with reperfused myocardial infarct, arterial hypertension with or without left ventricular hypertrophy, diabetes mellitus, hypercholesterolemia, syndrome X, hypertrophic cardiomyopathy and other diseases [5]. The assessment of CFR has also a prognostic value, so that a reduced CFR correlates with a negative prognosis [6]. Recently, new evidence underlined that not only the binary (normal-abnormal) response in CFR but the continuous spectrum of CFR value is a strong independent prognostic predictor in patients with known or suspected CAD [7].

Hirata et al [8] found a significant reduction of CFR in premenopausal women with SLE compared with age- and sex-matched controls. They concluded that microvascular impairment in SLE could be explained by functional alteration of endothelium which is responsible for the decrease vasodilation in response to pharmacological stress.

Turiel et al 9 detected a significant impairment of CFR in 25 early RA patients, with disease duration less than 1 year and without any anti-rheumatic therapy. The reduced CFR in absence of wall motion abnormalities at rest and during pharmacological stress showed a coro-
nary microcirculation involvement present in early RA and was associated with endothelial dysfunction.

Tissue Doppler Imaging (TDI) represents a new imaging modality which allows the measurement of myocardial velocities. Till now, TDI has been considered a reliable tool for the assessment of myocardial deformation, but this method is limited by angle-dependency and only deformation along the ultrasound beam can be derived from velocities, while myocardium deforms simultaneously in 3 dimensions [10]. Recently, Birdane et al [11] demonstrated that RA patients had a significant impairment of TDI biventricular diastolic functional parameters compared to healthy controls depending on age and use of steroids. To overcome TDI limitations, speckle tracking analysis has been introduced to evaluate myocardial strain along the longitudinal, circumferential and radial axis [12].

Another very useful application of echocardiography in systemic autoimmune diseases is the echo transesophageal approach which is widely recognized as more sensitive than the transthoracic evaluation for the detection of valvular lesions [13] and identification of intracardiac masses.

In particular, Turiel et al [14] observed a large prevalence (61%) of valvular thickening or vegetations and/or potential embolic sources by transesophageal echocardiographic approach in 56 patients with primary antiphospholipid syndrome followed up for 5 years.
2. Utility of coronary flow reserve assessment in systemic autoimmune diseases

Patients suffering from systemic autoimmune diseases (SADs), especially RA, present higher risk of acute myocardial infarction and stroke [15], correlated with disease duration [16] with higher frequency of silent myocardial infarction and sudden death compared to general population [17]. This increase in cardiovascular (CV) risk seems not depending on traditional risk factors, thus suggesting a dominating role of RA-related risk factors [18, 19]. During these last years, attempts of explaining the accelerated atherosclerosis pathogenic pathways in RA were made; Attention particularly focused importance of chronic systemic inflammatory process with high pro-inflammatory cytokines plasmatic levels. Presence of pro-atherogenic alterations such as dislipidemia, insulin-resistance, trombofilia and oxidative stress look favoring development of endothelial dysfunction that may be the initial stage of the atherosclerotic process [20, 21]. Arosio et al. [22], showed a reduced vasodilatation endothelium-dependant, changes in micro circle reactivity and an increased arterial stiffness in RA female patients.

Today non invasive evaluation of carotid median intimal thickness (IMT) is considered an early atherosclerosis clinical marker [23]. Kumeda et al. [24] observed in RA patients an increased IMT of common carotid and femoral artery, related to disease severity and duration. According to these evidences, Ciftci et al. [25] confirmed increased IMT and presence of reduced coronary flow reserve (CFR) in RA patients, correlating CV risk to disease duration. Moreover, Chung et al. [26], studied extension of coronary calcifications with CT, showing that patient with a long history of RA presents greater prevalence and severity of coronary calcifications compared to patients with early RA, also correlated with smoking and increase eritrosedimentation rate (ESR).

Nowadays, trans-thoracic echocardiographic evaluation of CFR by pharmacological stress (adenosine or dipyridamol) is considered a very useful exam as diagnose marker highly sensible (>90%) for coronary disease [27]. If associated with LV regional kinesis evaluation, acquires high specificity too. CFR value< 2 measured about at middle-distal tract of left anterior descending artery can accurately predict the presence of coronary significative stenosis. If epicardial vessels are free from significant stenosis a reduced CFR can be evidence of an alteration in coronary microcirculation in patients with reperfused myocardial infarction, high blood pressure with or without LV hypertrophy, diabetes mellitus, hypercholesterolemia, X syndrome, hypertrophic cardiomyopathy and collagen diseases. CFR measure has prognostic value in different pathologic conditions too[28].

Turiel et al. [29] showed a statistically significative variation of CFR among RA patients related with disease duration.

Endothelium function can be also studied through measure of asymmetric dymethylarginine (ADMA) plasmatic levels. Many clinical evidences support a close association between ADMA level and CV involvement in patients autoimmune diseases [30].
Higher ADMA plasmatic levels are reported in many conditions associated with high CV risk such as hypercholesterolemia, hypertriglyceridemia [31], peripheral artery disease [32], diabetes mellitus type II [33], acute coronary syndrome [34], chronic renal failure [35]. Moreover, Surdacki et al [36] evidenced in RA patient an association between high ADMA plasmatic levels and increased IMT at common carotid artery. Turiel et al. [37]observed an inverse correlation between ADMA and CFR in early stages of RA thus indicating a subclinical heart involvement already present at the beginning of the development of the disease.

Many clinical trials evidenced potential effects against atherosclerosis of therapies lead with disease modifying anti-rheumatic drugs (DMARDs), going beyond the simple control of inflammatory process and of disease activity (Tab. 1). In particular Hurlimann et al. [38] showed that anti-TNFα can not only reduce disease activity indexes, but also increase endothelial function in RA. Moreover, Sitta et al. [39] observed that long time treatment with DMARDs can reverse endothelial dysfunction, in early stages of disease.

<table>
<thead>
<tr>
<th>Farmaco</th>
<th>Posologia</th>
<th>Tempo approssimativo per l’azione</th>
<th>Documentazione attività ref.</th>
<th>Costo per terapia annuale ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Idrossiclorochina</td>
<td>200 mg 2 volte al giorno</td>
<td>2 – 6 mesi</td>
<td>11,12</td>
<td>1.056</td>
</tr>
<tr>
<td>Oro intramuscolo</td>
<td>25-50 mg i.m. ogni 2-4 sett</td>
<td>3 – 6 mesi</td>
<td>13</td>
<td>198</td>
</tr>
<tr>
<td>Azatioprina</td>
<td>50-150 mg al giorno</td>
<td>2 - 3 mesi</td>
<td>14</td>
<td>579 - 1.737</td>
</tr>
<tr>
<td>D- penicillamina</td>
<td>250-750 mg/die</td>
<td>3 – 6 mesi</td>
<td>15</td>
<td>865 - 2.595</td>
</tr>
<tr>
<td>Ciclosporina</td>
<td>25-4 mg/Kg/die</td>
<td>2 – 4 mesi</td>
<td>16</td>
<td>4.432 - 8.859</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>7,5-20 mg/sett i.m. o per os</td>
<td>1 – 2 mesi</td>
<td>17,18</td>
<td>orale 697 –1.859 i.m. 419 - 806</td>
</tr>
<tr>
<td>Sulfasalazina</td>
<td>100 mg 2-3 volte die</td>
<td>1 - 3 mesi</td>
<td>19 - 21</td>
<td>509 - 763</td>
</tr>
<tr>
<td>Leflunomide</td>
<td>20 mg al giorno</td>
<td>4 - 12 sett.</td>
<td>22,23</td>
<td>2.938</td>
</tr>
<tr>
<td>Infliximab (+ Methotrexate)</td>
<td>da pochi giorni a 4 mesi</td>
<td>24 - 26</td>
<td>13.940 - 36.694</td>
<td></td>
</tr>
<tr>
<td>Etanercept</td>
<td>25 mg sc 2 volte/sett.</td>
<td>da pochi giorni a 4 sett.</td>
<td>27 - 29</td>
<td>15.436</td>
</tr>
<tr>
<td>Anakinra</td>
<td>100 mg sc quotidie</td>
<td>-</td>
<td>30,31</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 1. Disease modifying anti-rheumatic drugs (DMARDs) in common use. (From American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 2002; 46: 328-46, modified).
In addition, Mäki-Petäjä et al. [40] in a recent study confirmed the efficacy of associating ezetimibe and simvastatin in reducing the inflammatory process, but also in improving aortic stiffness in RA. Anyway, the possible validation of efficacy of the therapy with statin and/or biological drugs in modifying the evolution of atherosclerosis needs further perspective clinical trials.

3. Conclusions

Subclinical CV involvement related to specific and non-specific risk factors is frequent in systemic autoimmunity diseases. It begins rapidly after the onset of the disease and progresses with disease duration. All cardiac structures may be affected, and the cardiac complications include a variety of clinical manifestations. As CV involvement is associated with an unfavorable prognosis, the early detection of subclinical cardiac involvement in asymptomatic SADs patients is essential and then modern techniques nowhere existing and in this chapter illustrated are very very important to reach such goal.

Conflict of interest

None

Author details

Maurizio Turiel¹, Luigi Gianturco¹, Vincenzo Gianturco² and Bruno Dino Bodini³

*Address all correspondence to: maurizio.turiel@unimi.it

1 Cardiology Unit, IRCCS Galeazzi Orthopedic Institute, Department of Biomedical Sciences for Health, University of Milan, Milan, Italy

2 Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatrics Sciences, Sapienza University of Rome, Italy

3 Rehabilitation Unit, IRCCS Galeazzi Orthopedic Institute, Italy

References


